<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>Insight数据库 | wechat-feeds</title><link>http://MzA4MzkzMDYyNw.favicon.privacyhide.com/favicon.ico</link><description>丁香园 Insight 数据库（db.dxy.cn），拥有申报、临床、上市、药企等 10 大核心数据。致力于分享医药行业政策解读、药企大事和药品申报情报等</description><managingEditor> (hellodword)</managingEditor><pubDate>Thu, 13 May 2021 19:19:02 +0800</pubDate><image><url>http://MzA4MzkzMDYyNw.favicon.privacyhide.com/favicon.ico</url><title>Insight数据库 | wechat-feeds</title><link>http://MzA4MzkzMDYyNw.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>四大榜单看懂中国医药上市公司</title><link>https://mp.weixin.qq.com/s/2OWygJk7mdir_LoQNucXKw</link><description></description><content:encoded><![CDATA[四大榜单看懂中国医药上市公司]]></content:encoded><pubDate>Thu, 13 May 2021 18:11:39 +0800</pubDate></item><item><title>恒瑞「瑞马唑仑」新适应症报上市</title><link>https://mp.weixin.qq.com/s/1SpiJSezlUKBj1PfOvOUBA</link><description></description><content:encoded><![CDATA[恒瑞「瑞马唑仑」新适应症报上市]]></content:encoded><pubDate>Thu, 13 May 2021 18:11:39 +0800</pubDate></item><item><title>首仿！北京百奥药业盐酸伊伐布雷定片即将获批</title><link>https://mp.weixin.qq.com/s/421UdYd3_wYhzhJP84fxkA</link><description></description><content:encoded><![CDATA[首仿！北京百奥药业盐酸伊伐布雷定片即将获批]]></content:encoded><pubDate>Thu, 13 May 2021 18:11:39 +0800</pubDate></item><item><title>刚刚！国内首款 Trop-2 ADC 报上市，拟优先审评</title><link>https://mp.weixin.qq.com/s/xEhk_tcMma0S8LQ-3mXeMw</link><description></description><content:encoded><![CDATA[刚刚！国内首款 Trop-2 ADC 报上市，拟优先审评]]></content:encoded><pubDate>Wed, 12 May 2021 18:12:36 +0800</pubDate></item><item><title>网售处方药放开在即：全民狂欢，还是头部盛宴？</title><link>https://mp.weixin.qq.com/s/dpZcZqJ1F9MnhddwDy8IrQ</link><description></description><content:encoded><![CDATA[网售处方药放开在即：全民狂欢，还是头部盛宴？]]></content:encoded><pubDate>Wed, 12 May 2021 18:12:36 +0800</pubDate></item><item><title>豪森药业「阿美替尼」一线 NSCLC 适应症报上市，拟优先审评</title><link>https://mp.weixin.qq.com/s/0xeYKgeUxElat5vI51UF7Q</link><description></description><content:encoded><![CDATA[豪森药业「阿美替尼」一线 NSCLC 适应症报上市，拟优先审评]]></content:encoded><pubDate>Wed, 12 May 2021 18:12:36 +0800</pubDate></item><item><title>奥希替尼仿制药来了！江苏万邦国内首家报产</title><link>https://mp.weixin.qq.com/s/zkZ8iLtCbdbofafXSippTA</link><description></description><content:encoded><![CDATA[奥希替尼仿制药来了！江苏万邦国内首家报产]]></content:encoded><pubDate>Wed, 12 May 2021 18:12:36 +0800</pubDate></item><item><title>恒瑞 SHR-1905 获批临床，哮喘领域第三款单抗</title><link>https://mp.weixin.qq.com/s/BdweWJsM4JdcMRRITp5oeQ</link><description></description><content:encoded><![CDATA[恒瑞 SHR-1905 获批临床，哮喘领域第三款单抗]]></content:encoded><pubDate>Wed, 12 May 2021 18:12:36 +0800</pubDate></item><item><title>重磅升白药！万春药业「普那布林」报上市，拟纳入优先审评</title><link>https://mp.weixin.qq.com/s/WeKpc_4SRONIac8CTGQmVw</link><description></description><content:encoded><![CDATA[重磅升白药！万春药业「普那布林」报上市，拟纳入优先审评]]></content:encoded><pubDate>Wed, 12 May 2021 18:12:36 +0800</pubDate></item><item><title>礼来与 MiNA 公司达成全球合作，开发 RNA 激活疗法</title><link>https://mp.weixin.qq.com/s/DFfgRcJpeDC5NbGmb6STdg</link><description></description><content:encoded><![CDATA[礼来与 MiNA 公司达成全球合作，开发 RNA 激活疗法]]></content:encoded><pubDate>Wed, 12 May 2021 18:12:36 +0800</pubDate></item><item><title>2021 年 4 月 CDE 药品审评报告</title><link>https://mp.weixin.qq.com/s/4IRp9cZXz73isjlOjdyjmA</link><description></description><content:encoded><![CDATA[2021 年 4 月 CDE 药品审评报告]]></content:encoded><pubDate>Tue, 11 May 2021 18:22:43 +0800</pubDate></item><item><title>华东医药/MediBeacon 1 类新药 MB-102 注射液获批临床</title><link>https://mp.weixin.qq.com/s/7x4AkgAgaZxpbs1EZTordQ</link><description></description><content:encoded><![CDATA[华东医药/MediBeacon 1 类新药 MB-102 注射液获批临床]]></content:encoded><pubDate>Tue, 11 May 2021 18:22:43 +0800</pubDate></item><item><title>用于重度哮喘，安进重磅单抗 Tezepelumab 递交 BLA，国内已启动 III 期临床</title><link>https://mp.weixin.qq.com/s/NoOowl6YcNNl5LPmQwtLlg</link><description></description><content:encoded><![CDATA[用于重度哮喘，安进重磅单抗 Tezepelumab 递交 BLA，国内已启动 III 期临床]]></content:encoded><pubDate>Tue, 11 May 2021 18:22:43 +0800</pubDate></item><item><title>首付款 9750 万元，复宏汉霖获 BRAF 抑制剂独家许可</title><link>https://mp.weixin.qq.com/s/xa2o7rdTcMR_-D9_pjKS8g</link><description></description><content:encoded><![CDATA[首付款 9750 万元，复宏汉霖获 BRAF 抑制剂独家许可]]></content:encoded><pubDate>Tue, 11 May 2021 18:22:43 +0800</pubDate></item><item><title>5.5 亿美元！艾尔建美学收购 Soliton，扩大医美产品组合</title><link>https://mp.weixin.qq.com/s/BwvdE2_wMs7ehx7gydxuWw</link><description></description><content:encoded><![CDATA[5.5 亿美元！艾尔建美学收购 Soliton，扩大医美产品组合]]></content:encoded><pubDate>Tue, 11 May 2021 18:22:43 +0800</pubDate></item><item><title>刚刚！5 个第五批国采品种竞争格局生变，3 款仿制药首家过评</title><link>https://mp.weixin.qq.com/s/Iez0_sRREiUmHBFJyTXq3Q</link><description></description><content:encoded><![CDATA[刚刚！5 个第五批国采品种竞争格局生变，3 款仿制药首家过评]]></content:encoded><pubDate>Mon, 10 May 2021 18:40:50 +0800</pubDate></item><item><title>百济神州 PARP 抑制剂正式开卖，零售价 7000 元/盒</title><link>https://mp.weixin.qq.com/s/h7fSqKBi8Ougw3UzOtjaPg</link><description></description><content:encoded><![CDATA[百济神州 PARP 抑制剂正式开卖，零售价 7000 元/盒]]></content:encoded><pubDate>Mon, 10 May 2021 18:40:50 +0800</pubDate></item><item><title>高难度品种！石药集团「盐酸多柔比星脂质体注射液」首家过评</title><link>https://mp.weixin.qq.com/s/AbN6TbBlyO7XNWl_RATZoA</link><description></description><content:encoded><![CDATA[高难度品种！石药集团「盐酸多柔比星脂质体注射液」首家过评]]></content:encoded><pubDate>Mon, 10 May 2021 18:40:50 +0800</pubDate></item><item><title>科伦药业 LAG-3 单抗启动临床</title><link>https://mp.weixin.qq.com/s/TQ1u5sov9YIOHRZyXbOJ0w</link><description></description><content:encoded><![CDATA[科伦药业 LAG-3 单抗启动临床]]></content:encoded><pubDate>Mon, 10 May 2021 18:40:50 +0800</pubDate></item><item><title>破解「进院难」，谈判药品「双通道」管理机制官方解读来了！</title><link>https://mp.weixin.qq.com/s/9pC53o-j4AeSWDEWno0jIQ</link><description></description><content:encoded><![CDATA[破解「进院难」，谈判药品「双通道」管理机制官方解读来了！]]></content:encoded><pubDate>Mon, 10 May 2021 18:40:50 +0800</pubDate></item></channel></rss>